Alison J. Rodger

Alison J. Rodger

Auto-generated profile, based on publicly available information

Alison J. Rodger

University College London, London, UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2016 in JAMA
Verified
Journal Article
Open access
PDF file
ARAlison J. Rodger
Alison J. Rodger
VCValentina Cambiano
Valentina Cambiano
TBTina Bruun
Tina Bruun
PVPietro Vernazza
Pietro Vernazza
SCSimon Collins
Simon Collins
FGfor the PARTNER Study Group
for the PARTNER Study Group
Quiz Ref ID Several studies have demonstrated that HIV-positive people taking antiretroviral therapy (ART) who have low plasma HIV-1 RNA load have markedly reduced infectiousness for sexual transmission.1-4 In particular, the HPTN 052 study, conducted primarily in heterosexual serodifferent couples, demonstrated a 96% reduction in HIV transmission risk in HIV-positive adults randomized to early ART initiation compared with the group that deferred treatment.4 As a result, World Health Organization guidelines now recommend that ART should be offered to all HIV-positive people, irrespective of CD4 cell count, to reduce risk of transmission.5

1 June 2019 in The Lancet
Verified
Journal Article
Open access
ARAlison J Rodger
Alison J Rodger
VCValentina Cambiano
Valentina Cambiano
TBTina Bruun
Tina Bruun
PVPietro Vernazza
Pietro Vernazza
SCSimon Collins
Simon Collins
NJNuno Janeiro
Nuno Janeiro
The level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral therapy (ART) is limited compared with the evidence available for transmission risk in heterosexual couples. The aim of the second phase of the PARTNER study (PARTNER2) was to provide precise estimates of transmission risk in gay serodifferent partnerships. The PARTNER study was a prospective observational study done at 75 sites in 14 European countries. The first phase of the study (PARTNER1; Sept 15, 2010, to May 31, 2014) recruited and followed up both heterosexual and gay serodifferent couples (HIV-positive partner taking suppressive ART) who reported condomless sex, whereas the PARTNER2 extension (to April 30, 2018) recruited and followed up gay couples only. At study visits, data collection included sexual behaviour questionnaires, HIV testing (HIV-negative partner), and HIV-1 viral load testing (HIV-positive partner). If a seroconversion occurred in the HIV-negative partner, anonymised phylogenetic analysis was done to compare HIV-1 pol and env sequences in both partners to identify linked transmissions. Couple-years of follow-up were eligible for inclusion if condomless sex was reported, use of pre-exposure prophylaxis or post-exposure prophylaxis was not reported by the HIV-negative partner, and the HIV-positive partner was virally suppressed (plasma HIV-1 RNA <200 copies per mL) at the most recent visit (within the past year). Incidence rate of HIV transmission was calculated as the number of phylogenetically linked HIV infections that occurred during eligible couple-years of follow-up divided by eligible couple-years of follow-up. Two-sided 95% CIs for the incidence rate of transmission were calculated using exact Poisson methods. Between Sept 15, 2010, and July 31, 2017, 972 gay couples were enrolled, of which 782 provided 1593 eligible couple-years of follow-up with a median follow-up of 2·0 years (IQR 1·1-3·5). At baseline, median age for HIV-positive partners was 40 years (IQR 33-46) and couples reported condomless sex for a median of 1·0 years (IQR 0·4-2·9). During eligible couple-years of follow-up, couples reported condomless anal sex a total of 76 088 times. 288 (37%) of 777 HIV-negative men reported condomless sex with other partners. 15 new HIV infections occurred during eligible couple-years of follow-up, but none were phylogenetically linked within-couple transmissions, resulting in an HIV transmission rate of zero (upper 95% CI 0·23 per 100 couple-years of follow-up). Our results provide a similar level of evidence on viral suppression and HIV transmission risk for gay men to that previously generated for heterosexual couples and suggest that the risk of HIV transmission in gay couples through condomless sex when HIV viral load is suppressed is effectively zero. Our findings support the message of the U=U (undetectable equals untransmittable) campaign, and the benefits of early testing and treatment for HIV. National Institute for Health Research.

27 March 2013 in AIDS
Verified
Journal Article
Closed access
ARAlison J. Rodger
Alison J. Rodger
RLRebecca Lodwick
Rebecca Lodwick
MSMauro Schechter
Mauro Schechter
SDSteven Deeks
Steven Deeks
JAJanaki Amin
Janaki Amin
APAndrew Phillips
Andrew Phillips
Due to the success of antiretroviral therapy (ART), it is relevant to ask whether death rates in optimally treated HIV are higher than the general population. The objective was to compare mortality rates in well controlled HIV-infected adults in the SMART and ESPRIT clinical trials with the general population. Non-IDUs aged 20-70 years from the continuous ART control arms of ESPRIT and SMART were included if the person had both low HIV plasma viral loads (≤400 copies/ml SMART, ≤500 copies/ml ESPRIT) and high CD4(+) T-cell counts (≥350 cells/μl) at any time in the past 6 months. Standardized mortality ratios (SMRs) were calculated by comparing death rates with the Human Mortality Database. Three thousand, two hundred and eighty individuals [665 (20%) women], median age 43 years, contributed 12,357 person-years of follow-up. Sixty-two deaths occurred during follow up. Commonest cause of death was cardiovascular disease (CVD) or sudden death (19, 31%), followed by non-AIDS malignancy (12, 19%). Only two deaths (3%) were AIDS-related. Mortality rate was increased compared with the general population with a CD4(+) cell count between 350 and 499 cells/μl [SMR 1.77, 95% confidence interval (CI) 1.17-2.55]. No evidence for increased mortality was seen with CD4(+) cell counts greater than 500 cells/μl (SMR 1.00, 95% CI 0.69-1.40). In HIV-infected individuals on ART, with a recent undetectable viral load, who maintained or had recovery of CD4(+) cell counts to at least 500 cells/μl, we identified no evidence for a raised risk of death compared with the general population.

1 May 2017 in International Journal of Drug Policy
Verified
Journal Article
Closed access
JSJaney Sewell
Janey Sewell
AMAda Miltz
Ada Miltz
FLFiona C. Lampe
Fiona C. Lampe
VCValentina Cambiano
Valentina Cambiano
ASAndrew Speakman
Andrew Speakman
ARAlison J. Rodger
Alison J. Rodger

1 June 2019 in International Journal of Drug Policy
Verified
Journal Article
Open access
JSJaney Sewell
Janey Sewell
VCValentina Cambiano
Valentina Cambiano
ASAndrew Speakman
Andrew Speakman
FLFiona C. Lampe
Fiona C. Lampe
APAndrew Phillips
Andrew Phillips
ARAlison J. Rodger
Alison J. Rodger
Recent evidence has suggested that chemsex (the use of mephedrone, crystal methamphetamine and γ -hydroxybutyrate/ γ -butryolactone (GHB/GBL) to enable, enhance and prolong sexual interactions) has increased among men having sex with men (MSM) attending sexual health clinics in large UK cities. To date there has been no data from the UK or Europe that describes changes in chemsex over time within a cohort of MSM. The prospective cohort study, Attitudes to and Understanding Risk of Acquisition of HIV over Time (AURAH2), collected online questionnaire data from HIV negative or undiagnosed MSM (at enrolment) from 2015 to 2018, recruited from sexual health clinics. We aim to investigate changes in chemsex, three individual drugs associated with chemsex, frequency of chemsex sessions and measures of sexual behaviour, among the cohort of MSM over the study's 3 year follow-up period. In total 622 MSM completed at least one online questionnaire for the AURAH2 study, of which 400 (64.3%) were still engaged with the study within the last six months of follow-up. Prevalence of chemsex significantly declined during the follow-up from 31.8% (198/622) at the first online questionnaire, to 11.1% (8/72; p < 0.001) at the 9th. This decline was reflected in the proportion of MSM reporting use of two of the three individual chemsex drugs: mephedrone use had significantly declined from 25.2% at the first online questionnaire to 9.7% (p < 0.001) at the 9th, GHB/GBL use had also declined from 19.9% to 8.3% (p = 0.001). While crystal methamphetamine use declined, but not significantly (11.1%-6.9% [p = 0.289]). Most measures of sexual behaviour (any anal sex, group sex, recent HIV test and bacterial STI) also tended to decline over the follow-up period, with the exception of CLAI with more than one and more than two partners. Chemsex and use of two individual chemsex drugs (mephedrone and GHB/GBL) significantly declined over time among individuals in the study, alongside most measures of sexual behaviour with the exception of those related to CLAI. Focusing health promotion and HIV prevention, such as awareness of post-exposure prophylaxis (PEP) and access to pre-exposure prophylaxis (PrEP), on MSM that report chemsex, and in particular problematic chemsex, would be highly beneficial, potentially only necessary for a relatively short period of time for individuals, and could have long term benefits for HIV and STI prevention.

17 November 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
ARAlison Rodger
Alison Rodger
APAndrew Phillips
Andrew Phillips
JLJens Lundgren
Jens Lundgren
To the Editor: To recommend antiretroviral therapy (ART) as a policy to prevent transmission of the human immunodeficiency virus type 1 (HIV-1), it is critical to understand the risk of transmission through sex without condom use when the plasma viral load in patients receiving ART is fully suppressed. In addition to data reported by Cohen et al. (Aug. 11 issue),1 a 2009 meta-analysis2 showed no transmissions in 291 person-years, and the Partners in Prevention Study (ClinicalTrials.gov number, NCT00194519)3 showed one transmission in 273 person-years, but some couples used condoms. Accounting for the proportions of couples having sex without the use . . .